BOSTON--(BUSINESS WIRE)--Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present new data from a Phase 1 dose-escalation clinical trial evaluating the safety, tolerability, and pharmacokinetics of multiple repeated doses of CVL-865 (formerly PF-06372865) in healthy volunteers. The readout will be presented at the 2019 American Epilepsy Society Meeting, taking place from December 6-10 in Baltimore, Maryland. CVL-865 is a novel 2/3/5-subtype selective GABAA receptor positive allosteric modulator that is being investigated for the treatment of epilepsy.

Details of the poster presentation are as follows:

Title: Safety, tolerability, and pharmacokinetics of multiple repeated doses of the 2/3/5-subtype selective GABAA positive allosteric modulator PF-06372865 in healthy volunteersAuthors: Rachel Gurrell, Mark Whitlock, Adam OgdenPoster Session #: 2.225Date/Time: Sunday, December 8, 2019 from 10:00AM 4:00PM ETLocation: The Baltimore Convention Center, Baltimore

About Cerevel TherapeuticsCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company seeks to unlock the science surrounding new treatment opportunities through understanding the neurocircuitry of neuroscience diseases and associated symptoms. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including Parkinsons, epilepsy, schizophrenia and substance use disorders. Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit http://www.cerevel.com.

Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential of our research and development programs and the potential attributes and benefits of our product candidates. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

View original post here:
Cerevel Therapeutics to Present Safety, Tolerability, and Pharmacokinetics Results From Phase 1 Trial of CVL-865 - Business Wire